Researchers have developed a novel compound, FLAV-27, that targets the enzyme G9a to therapeutically reprogram the epigenome of neurons, offering a new strategy for Alzheimer's disease treatment. Unlike current drugs focusing on amyloid-beta plaques, FLAV-27 addresses upstream changes in gene expression, potentially reversing cognitive decline. FLAV-27 inhibits G9a, an enzyme involved in epigenetic regulation that silences genes crucial for brain cell development and memory. Promising results have been observed in cell experiments, nematodes, and mice, where FLAV-27 restored memory performance, social behavior, and synaptic function. This epigenetic approach represents a significant departure from existing therapies and holds potential for modifying the disease's underlying molecular mechanisms, though human trials are still a distant prospect.